Skip to main content
. 2021 Apr 13;66:103327. doi: 10.1016/j.ebiom.2021.103327

Fig. 5.

Fig 5

Erlotinib sensitivity in SMAD4 altered PDAC patients. (a) Forrest plot of multivariable cox hazard model for the interaction of SMAD4 status and treatment arm, containing all clinical baseline characteristics. (b) Kaplan-Meier curve comparing OS between both treatment arms in SMAD4 altered (SMAD4alt) and SMAD4 wild-type (WT) patients (2-sided log-rank test).